Syntekabio

Biotechnology & Healthcare
KOSDAQ

Syntekabio, founded in 2009, is a precision medical new drug development company that utilizes AI technology based on genomic big data, which was invested by ETRI (Electronics and Telecommunications Research Institute). It is a genetic big data research company with big data-based algorithm Personal Genome Map Platform (PMAP), and manages and analyzes large amounts of bio data and dielectric analysis using high performance and high efficiency supercomputers. Syntekabio derived 30 types of candidate materials that represent the inhibitory effect on COVID-19 by using Deep Matcher (a technology that simulates protein ligand complex interactions with 3D virtual graphics according to changes in the physical environment), which is its own AI new drug platform, and recently, has identified one type of final candidate material that can expect the prevention effect of COVID-19 at a similar level to remdesivir.